Pharm
Ensifentrine
search
Ensifentrine
, Ohtuvayre
See Also
Phosphodiesterase Inhibitors in COPD
COPD Management
Indications
Severe, refractory
COPD
with
Chronic Bronchitis
and frequent exacerbations
Mechanism
Combined PDE3 and
PDE4 Inhibitor
Increases lung intracellular cAMP
Bronchodilates and reduces airway inflammation
Medications
Ensifentrine Inhalation aqueous suspension: 3 mg/2.5 mL (unit-dose ampules)
Dosing
Shake Ensifentrine ampule before nebulizing (solution may appear cloudy and yellow)
Nebulize 3 mg (one ampule) twice daily
Adverse Effects
Uncommon adverse effects
Paradoxical bronchospasm
Suicidality
Hypertension
Diarrhea
Urinary Tract Infection
s
Back Pain
Safety
Unknown safety in pregnancy
Unknown safety in
Lactation
Efficacy
Efficacy data is limited as of 2024
Very expensive as of 2024 (approaches $3000/month)
Resources
Ensifentrine (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e6433c98-41a0-4f99-8f7f-d0e9db6e3f40
References
(2024) Presc Lett 31(9): 51
Type your search phrase here